Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Telo Genomics Corp V.TELO

Alternate Symbol(s):  TDSGF

Healthcare Industrials Biotechnology Conglomerates
Telo Genomics Corp. is a biotech company pioneering the telomere platform in the industry with applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. The Company's lead application, TELO-MM is being developed to provide actionable information to medical professionals in the treatment of multiple myeloma, a form of blood cancer. Its clinical studies and product development design includes TeloView SMM, TeloView Test to Predict Patient Resistance to Treatment, development in collaboration with the Mayo Clinic and TeloView Test to monitor minimal residual disease in MM patients. The Company, by combining quantitative analysis of three-dimensional telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, is developing products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers.


TSXV:TELO - Post by User

Telo Genomics Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(8)
•••
Post by toasted101on Apr 23, 2020 9:26pm
335 Views
Post# 30947693

Telo Genomics, Knight distribution agreement terminated

Telo Genomics, Knight distribution agreement terminated
 
 
 
 
 
 

Telo Genomics, Knight distribution agreement terminated

Telo Genomics Corp (2) (C:TELO)
Shares Issued 16,013,850
Last Close 4/23/2020 $0.16
Thursday April 23 2020 - Property Agreement

The TSX Venture Exchange has accepted for expedited filing documentation pertaining to an agreement dated April 20, 2020, between Telo Genomics Corp. and Knight Therapeutics Inc., pursuant to which the parties agreed to terminate a distribution, licence and supply agreement dated July 21, 2016. In consideration, the company will pay $5,000 and issue 50,000 share purchase warrants, each exercisable for one share at a price of 25 cents per share for a five-year period.

© 2020 Canjex Publishing Ltd.
Telo Genomics, Knight distribution agreement terminated

Telo Genomics Corp (2) (C:TELO)
Shares Issued 16,013,850
Last Close 4/23/2020 $0.16
Thursday April 23 2020 - Property Agreement

The TSX Venture Exchange has accepted for expedited filing documentation pertaining to an agreement dated April 20, 2020, between Telo Genomics Corp. and Knight Therapeutics Inc., pursuant to which the parties agreed to terminate a distribution, licence and supply agreement dated July 21, 2016. In consideration, the company will pay $5,000 and issue 50,000 share purchase warrants, each exercisable for one share at a price of 25 cents per share for a five-year period.

© 2020 Canjex Publishing Ltd.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities